Liang X, Bi S, Yang W, et al. Evaluation of the impact of hepatitis B vaccination among children born during 1992-2005 in China. J Infect Dis[J], 2009, 200(1):39-47.
[2]
Yan H, Zhong G, Xu G, et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus[J]. elife, 2012, 1: e00049.
[3]
Watashi K, Sluder A, Daito T, et al. Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter NTCP[J]. Hepatology, 2014, 59(5):1726-1737.
[4]
Nkongolo, S, Ni Y, Lempp FA, et al. Cyclosporin A inhibits Hepatitis B and Hepatitis D Virus entry by Cyclophilin-independent interference with the NTCP receptor[J]. J Hepatol, 2014, 60(4):723-31.
[5]
Lucifora J, Esser K, Protzer U. Ezetimibe blocks hepatitis B virus infection after virus uptake into hepatocytes[J]. Antiviral Res, 2013, 97(2), 195-197.
[6]
Ni Y, Lempp FA, Mehrle S, et al. Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes[J]. Gastroenterology,2014, 146(1):1070-1083.
[7]
Watashi K, Sluder A, Daito T, et al. Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter NTCP[J].Hepatology, 2014, 59(5):1726-1737.
[8]
Yan H, Peng B, Liu Y, et al.Viral entry of Hepatitis B and D viruses and bile salts transportation share common molecular determinants on sodium taurocholate cotransporting polypeptide[J]. J Virol, 2014, 88(6):3273-3284.
Liaw YF, Jia JD, Chan HL, et al. Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C. Hepatology 2011;54:1591-1599.
[11]
Li W C, Wang M R, Kong L B, et al. Peginterferon alpha-based therapy for chronic hepatitis B focusing on HBsAg clearance or seroconversion: A meta-analysis of controlled clinical trials[J]. BMC Infectious Diseases, 2011, 11:165.
[12]
Wei W, Wu Q, Zhou J, et al. A Better Antiviral Efficacy Found in Nucleos(t)ide Analog (NA) Combinations with Interferon Therapy than NA Monotherapy for HBeAg Positive Chronic Hepatitis B: A Meta-Analysis[J]. Int J Environ Res Public Health, 2015, 12(8):10039-10055.
[13]
Ning Q, Han M, Sun Y, et al. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial) [J]. J Hepatol, 2014;61:777-784.
[14]
Hu P, Jia S, Zhang W, et al. A multi-center randomized study on the efficacy and safety of switching to peginterferon alpha-2a (40KD) for 48 or 96 weeks in HBeAg positive CHB patients with a prior NUC history for 1 to 3 years: an interim analysis of NEW SWITCH study[J]. Hepatology, 2014;60:1273a-1274a.
[15]
Lin Z, Xin Y, Dong Q, et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis.Hepatology[J], 2011, 53(3):726-736.
[16]
Rossi E, Adams LA, Bulsara M, et al. Assessing liver fibrosis with serum marker models[J]. Clin Biochem Rev, 2007;28(1):3-10.
[17]
Hui AY, Chan HL, Wong VW, et al.Identification of chronic hepatitis B patients without significant liver fibrosis by a simple noninvasive predictive model. Am J Gastroenterol, 2015,100(3):616-623.
[18]
Zeng MD, Lu LG, Mao YM et al. Prediction of significant fibrosis in HBeAg-positive patients with chronic hepatitis B by a noninvasive model[J].Hepatology, 2005;42:1437-1445.
[19]
Poynard T, Munteanu M, Deckmyn O, et al. Applicability and precautions of use of liver injury biomarker FibroTest. A reappraisal at 7 years of age[J]. BMC Gastroenterol, 2011;11:39.
[20]
Chou R, Wasson N. Blood tests to diagnose fibrosis or cirrhosis in patients chronic hepatitis C virus infection: a systematic review. Ann Intern Med,2013,158(11):371-372.
[21]
Poynard T, Morra R, Halfon P, et al. Meta-analyses of Fibrotest diagnostic value in chronic liver disease[J]. BMC Gastroenterol, 2007, 7:40.
[22]
Lin ZH, Xin YN, Dong QJ, et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis[J]. Hepatology, 2011, 53:726-736.
[23]
European Association for the Study of the Liver,Asociación Latinoamericana para el Estudio del Hígado. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis[J]. J Hepatol, 2015(1):237-264.
2016, Vol. 27 
